Cost-effectiveness of enhancing adherence with oral bisphosphonates treatment in osteoporotic women: An empirical approach based on healthcare utilisation databases

BMJ Open

Volumn 4, Issue 3, 2014, Pages

  Scotti, Lorenza ^a   Arfè, Andrea ^a   Zambon, Antonella ^a   Merlino, Luca ^b   Corrao, Giovanni ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b Operative Unit of Territorial Health Services   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; RISEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

ADULT; ARTICLE; CHARLSON COMORBIDITY INDEX; CHRONIC DISEASE; COHORT ANALYSIS; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; ITALY; MAJOR CLINICAL STUDY; MEDICATION COMPLIANCE; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRESCRIPTION; RETROSPECTIVE STUDY; SURVIVAL TIME; AGE; AGED; COMPLICATION; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; FRACTURES, BONE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; QUALITY ADJUSTED LIFE YEAR; RISK FACTOR; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; COMORBIDITY; COST-BENEFIT ANALYSIS; DIPHOSPHONATES; DRUG COSTS; FEMALE; FRACTURES, BONE; HEALTH CARE COSTS; HUMANS; ITALY; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; QUALITY-ADJUSTED LIFE YEARS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84897477489     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-003758     Document Type: Article

References (45)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-95.
2. Cashman KD. Diet, nutrition, and bone health. J Nutr 2007;137:2507S-12S. (Pubitemid 350058727)
3. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-41. (Pubitemid 26411651)
4. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000;11:83-91. (Pubitemid 30099515)
5. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81:1013-22. (Pubitemid 44175011)
6. Downey TW, Foltz SH, Boccuzzi SJ, et al. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J 2006;99:570-5. (Pubitemid 43999919)
7. Yood RA, Emani S, Reed JI, et al. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003;14:965-8. (Pubitemid 40824268)
8. Blouin J, Dragomir A, Moride Y, et al. Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women. Br J Clin Pharmacol 2008;66:117-27. (Pubitemid 351822168)
9. Mullins CD, Ohsfeldt RL. Modelling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy. J Manag Care Pharm 2003;9:150-8.
10. McDonald HP, Garg A, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002;288:2868-79. (Pubitemid 35425073)
11. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd edn. New York: Oxford University Press, 1997.
12. Ström O, Borgström F, Sen SS, et al. Cost-effectiveness of alendronate in the treatment of postmenopausal women in 9 European contries - an economic evaluation based on the fracture intervention trial. Ostoporos Int 2007;18:1047-61. (Pubitemid 47020004)
13. Cotté FE, Fautrel B, De Pouvourville G. A Markov model simulation of the impact of treatment persistence in post-menopausal osteoporosis. Med Decis Making 2009;29:125-39.
14. Patrick A, Schousboe JT, Losina E, et al. The economics of improving medication adherence in osteoporosis: validation and application of a simulation model. J Clin Endocrinol Metab 2011;96:2762-70.
15. Simon G, Wagner E, Vonkorff M. Cost-effectiveness comparisons using "real world" randomized trials: the case of new antidepressant drugs. J Clin Epidemiol 1995;48:363-73.
16. Rothwell PM. External validity of randomised controlled trials: "To whom do the results of this trial apply?" Lancet 2005;365:82-93. (Pubitemid 40082150)
17. Sheldon TA. Problems of using modelling in the economic evaluation of health care. Health Econ 1996;5:1-11.
18. Corrao G, Cesana G, Merlino L. Pharmacoepidemiological research and the linking of electronic health care databases available in the Italian region of Lombardy. BioMed Stat Clin Epidemiol 2008;2:117-25.
19. Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases. Value Health 2007;10:3-12. (Pubitemid 46161090)
20. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19.
21. Marubini E, Valsecchi MG. Analysing survival data from clinical trials and observational studies. New York: John Wiley & Sons, 1995.
22. Forbes C, Evans M, Hastings N, et al. Statistical distributions. 4th edn. Hoboken: John Wiley & Sons, 2011.
23. Neymark N, Adriaenssen I, Gorlia T, et al. Estimating survival gain for economic evaluations with survival time as principal endpoint: a cost-effectiveness analysis of adding early hormonal therapy to radiotherapy in patients with locally advanced prostate cancer. Health Econ 2002;11:233-48. (Pubitemid 34284848)
24. Lin DY. On the Breslow estimator. Lifetime Data Anal 2007;13:471-80.
25. Karrison T. Use of Irwin's restricted mean as an index for comparing survival in different treatment groups - interpretation and power considerations. Controlled Clin Trials 1997;18:151-67. (Pubitemid 27225892)
26. Wang H, Zhao H. A study on confidence intervals for incremental cost-effectiveness ratios. Biom J 2008;50:505-14.
27. Steenland K, Greenland S. Monte Carlo sensitivity analysis and Bayesian analysis of smoking as an unmeasured confounder in a study of silica and lung cancer. Am J Epidemiol 2004;160:384-90.
28. Wu Q, Liu J, Gallegos-Orozco JF, et al. Depression, fracture risk, and bone loss: a meta-analysis of cohort studies. Osteoporos Int 2010;21:1627-35.
29. Mussolino ME. Depression and hip fracture risk: the NHANES I epidemiologic follow-up study. Public Health Rep 2005;120:71-5. (Pubitemid 40965706)
30. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment. Meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med 2000;160:2101-7. (Pubitemid 30482715)
31. Piscitelli P, Gimigliano F, Gatto S, et al. Hip fractures in Italy: 2000-2005 extension study. Osteoporos Int 2010;21:1323-30.
32. Maravic M, Jouaneton B, Vainchtock A, et al. Economic burden of osteoporosis in women: data from the 2008 French hospital database (PMSI). Clin Exp Rheumatol 2012;30:222-7.
33. Tarride JE, Hopkins RB, Leslie WD, et al. The burden of illness of osteoporosis in Canada. Osteoporos Int 2012;23:2591-600.
34. Hiligsmann M, Rabenda V, Bruyère O, et al. The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients. Health Policy 2010;96:170-7.
35. Briggs A, Sculpher M. An introduction to Markov modeling for economic evaluations. Pharmacoeconomics 1998;13:397-409. (Pubitemid 28140699)
36. Hiligsmann M, Rabenda V, Gathon HJ, et al. Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 2010;86:202-10.
37. Corrao G, Parodi A, Zambon A, et al. Reduced discontinuation of antihypertensive treatment by two drug combination as 1st step. Evidence from daily life practice. J Hypertens 2010;28:1584-90.
38. Danzon PM, Furukawa MF. International prices and availability of pharmaceuticals in 2005. Drugs spending differences reflect availability and use, not just prices. Health Aff 2011;27:221-33.
39. Gleeson T, Iversen MD, Avorn J, et al. Interventions to improve adherence and persistence with osteoporosis medications: a systematic literature review. Osteoporos Int 2009;20:2127-34.
40. Chapman RH, Ferrufino CP, Kowal SL, et al. The cost and effectiveness of adherence-improving interventions for antihypertensive and lipid-lowering drugs. Int J Clin Pract 2010;64:169-81.
41. Solomon DH, Iversen MD, Avorn J, et al. Osteoporosis telephonic intervention to improve medication regimen adherence: a large, pragmatic, randomized controlled trial. Arch Intern Med 2012;172:477-83.
42. Fitz-Simon N, Bennett K, Feely J. A review of studies of adherence with antihypertensive drugs using prescription databases. Ther Clin Risk Manag 2005;1:93-106.
43. Copeland KT, Checkoway H, McMichael AJ, et al. Bias due to misclassification in the estimation of relative risk. Am J Epidemiol 1997;105:488-95.
44. Pressman A, Forsyth B, Ettinger B, et al. Initiation of osteoporosis treatment after bone mineral density testing. Osteoporos Int 2001;12:337-42. (Pubitemid 32606455)
45. Rossini M, Bianchi G, Di Munno O, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 2006;17:914-21. (Pubitemid 43781506)